A Phase 1, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Single Oral Dose of 5 mg Vortioxetine in Subjects With Normal Hepatic Function or Severe Hepatic Impairment
Phase of Trial: Phase I
Latest Information Update: 03 Feb 2016
At a glance
- Drugs Vortioxetine (Primary)
- Indications Anxiety disorders; Generalised anxiety disorder; Major depressive disorder
- Focus Pharmacokinetics
- Sponsors Takeda
- 03 Jun 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 25 Jul 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 25 Jun 2014 New trial record